港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

719.918

+3.9520.55%

漲家數：15

跌家數：15

平家數：4

市盈率：- -

高：728.504

開：715.966

低：704.159

收：715.966

成交量：1.03億

成交額：37.60億

市值：4,603.13億

流通市值：4,086.12億

資料載入中...

總覽新聞資訊

華領醫藥－Ｂ(02552)出現大手賣出370萬股，成交價$3.6，涉資1.332千萬

阿斯达克财经

九強生物(300406.SZ)子公司取得一項醫療器械註冊證

貴陽市花溪區市場監管局：守護藥械安全，築牢民生屏障

中国质量新闻网

CMEF國產替代「風向標」觀察：從高端技術突圍到生態領跑，國產醫療器械邁入全鏈條自主可控新時代｜2026智·躍遷

华夏时报网

港股異動 | 康寧傑瑞製藥-B(09966)早盤升逾12% KN026商業化臨近即將貢獻新增量

創新藥概念震盪回升君實生物升逾10%

每日经济新闻

華創證券：AI製藥進入快速發展階段從概念驗證向商業化兑現轉變

7.45億美元！創新藥龍頭再獲天價大單！

【灣區早參】深圳各口岸一季度出入境人員超7300萬人次；廣州新建加氫站最高補貼500萬

加科思-B於4月10日斥資49.45萬港元回購6.84萬股

創新藥龍頭再獲天價大單，一季度淨利約去年全年2倍

21世纪经济报道

智通港股早知道 | 香港首批穩定幣發行人牌照落地伊美第三輪談判雙方存在嚴重分歧

海思科與艾伯維簽署Nav1.8抑制劑授權許可協議；浙江醫藥擬分拆子公司新碼生物至港交所主板上市丨醫藥早參

每日经济新闻

多家醫療器械上市公司拓展海外市場成效顯著

行業觀察｜他克莫司滴眼液價格被炒到3000多元，折射行業困境：我國高端眼科製劑市場依賴進口

每日经济新闻

1900億「醫械茅」，淨利潤大降30%

21世纪经济报道

康希諾生物(06185)：嬰幼兒用DTcP獲得中國國家藥監局NDA批准

智通财经网

瞄準創新藥板塊！基金經理，新打法曝光！

今年我國已批准十餘款創新藥，跨國藥企探索多元化合作模式

榮昌生物(09995.HK)維迪西妥單抗第五項新適應症上市申請獲批

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":719.91754,"timestamp":1776413292136,"preClose":715.96594,"halted":0,"volume":103129317,"delay":0,"changeRate":0.005519,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":3.951599,"latestTime":"04-17 16:00:00","open":715.96594,"high":728.5041,"low":704.15936,"amount":3759884233,"amplitude":0.034003,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"pbRate":5.639176,"peRate":-94.270914,"turnoverRate":0.00368,"increases":14,"decrements":17,"flats":2,"marketCap":460313417856,"floatMarketCap":408611897616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":728.5041,"amplitude":0.034003,"preClose":715.96594,"low":704.15936,"pbRate":"5.639176","latestPrice":719.91754,"volume":103129317,"delay":0,"open":715.96594,"prevYearClose":556.26263,"prevWeekClose":666.249,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":666.249,"twentyDayClose":575.488,"sixtyDayClose":612.872,"secType":"PLATE","market":"HK","turnoverRate":0.00368,"peRate":-94.270914,"marketCap":460313417856,"floatMarketCap":408611897616,"timestamp":1776413292136,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":15,"down":15,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627433975","title":"華領醫藥－Ｂ(02552)出現大手賣出370萬股，成交價$3.6，涉資1.332千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627433975","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627433975?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 16:08","pubTimestamp":1776067680,"startTime":"0","endTime":"0","summary":"[大手成交]华领医药－Ｂ(02552)在下午04:08出现大手卖出，成交量为370万，成交价为港币$3.6，涉资1.332千万。至目前为止，股价跌1.639%，今日最高价为$3.68，而最低价为$3.56，总成交量为580.589万股，总成交金额港币$2.09千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2604137059/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2604137059/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02552","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627438939","title":"九強生物(300406.SZ)子公司取得一項醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2627438939","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627438939?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 15:56","pubTimestamp":1776067001,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)公告，公司全资子公司福州迈新生物技术开发有限公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品名称为：雌激素受体抗体试剂(免疫组织化学法)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","09996","BK0028","BK0046","BK0077","BK0012","BK0239","BK1583","300406","159883","BK1574","BK1100","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627484438","title":"貴陽市花溪區市場監管局：守護藥械安全，築牢民生屏障","url":"https://stock-news.laohu8.com/highlight/detail?id=2627484438","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627484438?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 15:50","pubTimestamp":1776066600,"startTime":"0","endTime":"0","summary":"紧盯药品质量安全，规范经营秩序。此次行动共检查药品零售企业8家、化妆品经营使用单位8家、医疗器械经营使用单位5家，核查6个批次不合格化妆品。下一步，花溪区市场监督管理局将持续加大监管力度，聚焦重点领域、重点品种和关键环节，严厉打击各类违法违规行为，不断提升群众用药、用械、用妆的安全感、获得感与幸福感。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-13/doc-inhuixwy2345110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1222","BK1583","BK1100","09997","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627673482","title":"CMEF國產替代「風向標」觀察：從高端技術突圍到生態領跑，國產醫療器械邁入全鏈條自主可控新時代｜2026智·躍遷","url":"https://stock-news.laohu8.com/highlight/detail?id=2627673482","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627673482?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 14:24","pubTimestamp":1776061468,"startTime":"0","endTime":"0","summary":"当全球医疗产业格局深度调整，国产替代步入攻坚深水区，中国医疗器械企业持续突破底气来自哪里？4月9日至12日，第93届中国国际医疗器械博览会（CMEF）在上海国家会展中心盛大启幕，作为医疗器械全产业链的“风向标”盛会，众多国产企业带着自研创新产品携光而来，从高端设备的技术突围到核心部件的自主可控，从临床诊疗的精准赋能到家用健康的全面覆盖，全方位彰显“中国智造”的硬核实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702782510.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702782510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","159883","BK1222","09996","09997","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627485204","title":"港股異動 | 康寧傑瑞製藥-B(09966)早盤升逾12% KN026商業化臨近 即將貢獻新增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2627485204","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627485204?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 11:41","pubTimestamp":1776051708,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B早盘涨超12%，截至发稿，涨10.54%，报10.38港元，成交额2791.46万港元。东吴证券此前指出，康宁杰瑞目前进展最快的两款产品KN026源于JSKN003均已与石药集团达成国内合作。其中KN026在25年9月已经提交国内上市申请并获优先审评资格，用于2L HER2阳性胃癌患者，我们预计该适应症有望在2026年上市，如能在6月30日前获批则将有机会参与本年度医保目录谈判，加快KN026放量速度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"539122164097d66545bffd1deabe6e8d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","BK1161","BK4585","VXUS","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627460483","title":"創新藥概念震盪回升 君實生物升逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627460483","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627460483?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 10:47","pubTimestamp":1776048478,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，创新药概念盘中震荡回升，君实生物涨超10%，通化金马一度逼近涨停，常山药业、圣诺生物、荣昌生物、新诺威、三生国健涨幅靠前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702633963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702633963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","06978","BK1574","BK1515","688180","BK0239","BK1583","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483534","title":"華創證券：AI製藥進入快速發展階段 從概念驗證向商業化兑現轉變","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483534","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627483534?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 10:34","pubTimestamp":1776047676,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华创证券发布研报称，中国AI制药市场开始进入快速发展阶段，2024年市场规模达到5.6亿元，同比增长36.59%，2025年市场规模突破6亿元。多维度利好共振推动AI制药进入快速发展通道。AI制药行业正处于从概念验证向商业化兑现转变的关键阶段，建议重点关注具有平台技术优势、临床管线进展积极、商业模式清晰的优质标的。2021年市场规模增速明显提升，达到100%，表明了中国AI制药市场开始进入快速发展阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHAT","AIPO","BK1191","BK1574","AGIX","01477","ARTY","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710069","title":"7.45億美元！創新藥龍頭再獲天價大單！","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627710069?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 09:19","pubTimestamp":1776043140,"startTime":"0","endTime":"0","summary":"4月12日，海思科宣布与美国公司AbbVie Group Holdings Ltd．签订Nav1.8抑制剂授权协议，将获得3000万美元首付款及最高7.15亿美元的里程碑付款，AbbVie还将支持相关开发费用。公司旗下选择性Nav1.8阻断剂HSK55718和HSK51155通过抑制痛觉神经异常放电，意在开发为疼痛治疗药物。　　生物医药领域的创新药对外授权交易持续活跃，近期海思科与艾伯维就Nav1.8抑制剂达成的授权协议进一步印证了这一趋势。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-13/doc-inhuihze5709901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627107559","title":"【灣區早參】深圳各口岸一季度出入境人員超7300萬人次；廣州新建加氫站最高補貼500萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627107559","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627107559?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 08:48","pubTimestamp":1776041288,"startTime":"0","endTime":"0","summary":"牌照于当日生效。5、广州新建加氢站最高补贴500万广州市城市管理和综合执法局近日分别印发《广州市城市管理和综合执法局关于落实燃气领域营商环境“小切口”改革工作措施的通知》及《广州市加氢站建设运营补贴专项资金申领工作指引》。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978692","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","BK1574","HK0000252160.HKD","BK1155","BK1154","00916","LU0531970944.HKD","LU2543165471.USD","HK0000252152.HKD","LU0054450605.USD","LU1023057109.AUD","LU0449515922.USD","01276","LU0359201885.HKD","LU0823040885.USD","BK1558","LU0359202008.SGD","LU0449509016.USD","BK1515","CPI","BK1594","HK0000500386.USD","LU0214875030.USD","BK1191","03317","LU0359201612.USD","BK1168","BK1161","00551","LU0254981946.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627102359","title":"加科思-B於4月10日斥資49.45萬港元回購6.84萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627102359","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627102359?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 08:16","pubTimestamp":1776039360,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　加科思-B（01167）发布公告，于2026年4月10日斥资49.45万港元回购6.84万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-13/doc-inhuiatq4960518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627104498","title":"創新藥龍頭再獲天價大單，一季度淨利約去年全年2倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2627104498","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627104498?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 07:47","pubTimestamp":1776037620,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　4月12日晚间，海思科连发三份重磅公告，交出了一份极具“反转色彩”的成绩单。　　据海思科2026年第一季度业绩预告，公司预计当期归属于上市公司股东的净利润为4.77亿元至5.57亿元，同比增长923.34%至1094.97%；扣除非经常性损益后的净利润为4.49亿元至5.29亿元，同比增长791.94%至950.86%。21快讯记者注意到，海思科仅一季度净利润，就已接近2025年全年2.60亿元净利润的约两倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-04-13/doc-inhuiath5799064.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-13/doc-inhuiath5799064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627389104","title":"智通港股早知道 | 香港首批穩定幣發行人牌照落地 伊美第三輪談判雙方存在嚴重分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=2627389104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627389104?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 07:18","pubTimestamp":1776035912,"startTime":"0","endTime":"0","summary":"牌照于今日生效。伊美第三轮谈判已结束 双方存在严重分歧总台记者当地时间12日获悉，伊朗与美国在伊斯兰堡举行的又一轮会谈已结束。伊朗方面消息称，伊朗与美国代表团在谈判中仍存在一些严重分歧。美伊谈判21小时未达成协议。盛宝银行首席投资策略师 Charu Chanana 表示，美伊谈判无果而终是一次倒退。美英担忧 AI 暴露金融业漏洞Anthropic 发布 AI 模型 Mythos 预览版，美国政府日前召集一批银行高管紧急开会，讨论相关问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7d08dbda469a470286c6f9b045c09156","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","BK4585","LU1861558580.USD","01773","LU1791807156.HKD","01729","AMZN","CRCD","LU0106831901.USD","ICRC","LUMN","BK1500","CCUP","BK1161","LU1861559042.SGD","LU2360107671.USD","BK1596","00005","LU1668664300.SGD","CRCO","CRCG","06088","688331","LU1861220207.SGD","AMD","06960","BK1583","C","06166","603083","688185","LU1861217088.USD","300748","LU1969619763.USD","NVDA","HSBC","AVGO","WFC","LU2328871848.SGD","06869","BAC","03317","BK1574","601869","BK4023","CRCA","BK1228","06680","06185","BK4588","BK1556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627110123","title":"海思科與艾伯維簽署Nav1.8抑制劑授權許可協議；浙江醫藥擬分拆子公司新碼生物至港交所主板上市丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2627110123","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627110123?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 07:02","pubTimestamp":1776034948,"startTime":"0","endTime":"0","summary":"丨2026年4月13日星期一丨NO.1海思科：一季度归母净利润同比预增923%~1095%，与艾伯维签署Nav1.8抑制剂授权许可协议4月12日，海思科公告称，预计2026年一季度归属于上市公司股东的净利润为4.77亿元~5.57亿元，比上年同期增长923.34%~1094.97%。公司积极拓展市场，创新药销售持续保持良好增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702375029.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702375029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","600216","BK0191","BK0028","BK0077","BK0239","IPOS","BK0033","BK1515","BK0188","09939","BK1161","002653","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627361105","title":"多家醫療器械上市公司拓展海外市場成效顯著","url":"https://stock-news.laohu8.com/highlight/detail?id=2627361105","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627361105?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 00:27","pubTimestamp":1776011220,"startTime":"0","endTime":"0","summary":"A股上市公司2025年年报进入密集披露期，截至4月12日记者发稿，已有多家医疗器械行业公司交出亮眼“成绩单”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702336177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09996","159883","BK1574","09997","BK1583","BK1100","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626709521","title":"行業觀察｜他克莫司滴眼液價格被炒到3000多元，折射行業困境：我國高端眼科製劑市場依賴進口","url":"https://stock-news.laohu8.com/highlight/detail?id=2626709521","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626709521?lang=zh_tw&edition=fundamental","pubTime":"2026-04-12 20:30","pubTimestamp":1775997041,"startTime":"0","endTime":"0","summary":"近日，他克莫司滴眼液在电商平台大幅涨价冲上微博热搜，部分商家将其标价推高至3000余元。《每日经济新闻》记者了解到，尽管他克莫司滴眼液的核心专利已于2023年到期，但目前仅有日本千寿制药一款产品获批上市。一位从事眼科药物研究的行业人士表示，国内至今没有一款等效的工业化仿制药获批上市的根本原因，在于高端滴眼液领域存在着极高的药学与制剂工艺壁垒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604123702250875.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604123702250875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626517211","title":"1900億「醫械茅」，淨利潤大降30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626517211","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626517211?lang=zh_tw&edition=fundamental","pubTime":"2026-04-12 18:08","pubTimestamp":1775988480,"startTime":"0","endTime":"0","summary":"　　近日，中国医疗器械行业的“一哥”，迈瑞医疗在2025年遭遇了上市以来的首次年度营收下滑。　　年报数据显示，迈瑞医疗全年实现营业收入332.82亿元，同比下降9.38%；归母净利润81.36亿元，同比下降30.28%；扣非归母净利润80.69亿元，同比下降29.48%。Wind数据统计，截至2026年4月9日，139家A股医疗器械企业中已有30家发布了2025年年报，整体实现营业收入708.58亿元，同比下降2.20%；实现归母净利润142.58亿元，同比下降19.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-12/doc-inhufuxw6411367.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-12/doc-inhufuxw6411367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09997","SINA","BK1574","BK1222","09996","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626172927","title":"康希諾生物(06185)：嬰幼兒用DTcP獲得中國國家藥監局NDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626172927","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626172927?lang=zh_tw&edition=fundamental","pubTime":"2026-04-12 18:07","pubTimestamp":1775988440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 公布，中国国家药品监督管理局已批准公司研发的婴幼儿用吸附无细胞百(三组分)白破联合疫苗的新药上市申请。公司的婴幼儿用DTcP为国内首款上市的组分百白破疫苗。公司的婴幼儿用DTcP为公司组分百白破疫苗产品组合中首个获得NDA批准的产品，公司累积了临床研发、质量控制、规模化生产等相关经验，有利于产品组合中其他候选疫苗上市进程的推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：婴幼儿用DTcP获得中国国家药监局NDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1191","BK1515","06185","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626617252","title":"瞄準創新藥板塊！基金經理，新打法曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2626617252","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626617252?lang=zh_tw&edition=fundamental","pubTime":"2026-04-12 17:43","pubTimestamp":1775986980,"startTime":"0","endTime":"0","summary":"伴随各类事件催化进入密集兑现周期，不少基金经理开始切换布局创新药对冲组合风险。　　为对冲持仓波动、稳住组合收益，在老龄化趋势中迎来景气度利好，兼具刚需弹性与防御属性的创新药赛道，正靠着密集的事件驱动逻辑，逐渐成为基金经理调仓避险的重要选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-12/doc-inhufuye5534581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626174480","title":"今年我國已批准十餘款創新藥，跨國藥企探索多元化合作模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2626174480","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626174480?lang=zh_tw&edition=fundamental","pubTime":"2026-04-12 16:33","pubTimestamp":1775982835,"startTime":"0","endTime":"0","summary":"国家药监局日前公布的最新数据显示，今年截至4月10日，国家药监局已批准上市了13款创新药，这些药物的治疗领域从抗肿瘤到降血糖、降血脂，覆盖多种关键疾病，其中包括6款首创新药（first-in-class药物）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604123702167681.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604123702167681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626171683","title":"榮昌生物(09995.HK)維迪西妥單抗第五項新適應症上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2626171683","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626171683?lang=zh_tw&edition=fundamental","pubTime":"2026-04-12 15:01","pubTimestamp":1775977260,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布，公司自主研发的维迪西妥单抗(代号：RC48，商品名：爱地希®)用于联合特瑞普利单抗治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症新药上市申请获中国国家药品监督管理局批准。此为维迪西妥单抗在中国获批的第五项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-10 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1517027/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1517027/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1064130708.USD","LU2328871848.SGD","09995","LU2488822045.USD","LU2148510915.USD","BK1583","LU1064131003.USD","BK0239","688331","LU1969619763.USD","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":7,"totalSize":243,"code":"91000000","status":"200"}]}}